Literature DB >> 24682601

Pazopanib: an alternative in taxane-resistant cutaneous angiosarcoma.

Mafumi Fujita1, Yuichiro Endo1, Akihiko Fujisawa1, Miki Tanioka1, Kenji Kabashima1, Yoshiki Miyachi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24682601     DOI： 10.1684/ejd.2014.2298

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  3 in total

1.  Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.

Authors:  Mami Adachi; Yuki Hoshino; Yusuke Izumi; Hiroki Sakai; Satoshi Takagi
Journal:  Can J Vet Res       Date:  2016-07       Impact factor: 1.310

2.  Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.

Authors:  Dai Ogata; Hiroto Yanagisawa; Kenji Suzuki; Kohei Oashi; Naoya Yamazaki; Tetsuya Tsuchida
Journal:  Med Oncol       Date:  2016-09-09       Impact factor: 3.064

3.  Clinical and dermoscopic features of atypical abdominal brachytherapy-induced angiosarcoma.

Authors:  Beata Bergler-Czop; Karolina Hadasik; Ligia Brzezińska-Wcisło
Journal:  Postepy Dermatol Alergol       Date:  2016-08-16       Impact factor: 1.837
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.